• Overcoming Metabolic Dependencies in IDH2-Mutant AML Researc

  2026-07-17

  Translational advances in acute myeloid leukemia (AML) therapy are increasingly shaped by the mechanistic understanding of metabolic rewiring in IDH2-mutant cells. This article explores how AG-221 (Enasidenib), a selective IDH2 R140Q inhibitor, not only suppresses pathological 2-hydroxyglutarate accumulation but also opens new strategic windows for combination therapies targeting metabolic dependencies such as those mediated by CD44. Integrating recent mechanistic discoveries and actionable protocol recommendations, we provide translational researchers with a roadmap to more effective preclinical and clinical studies—distinguishing this perspective from conventional product summaries through its depth, evidence integration, and forward-thinking guidance.

• Annexin V-PE Reagent: Optimizing Early Apoptosis Detection W

  2026-07-17

  Annexin V-PE Reagent empowers researchers to achieve rapid, sensitive, and reproducible apoptotic cell detection—crucial for CAR-T, immunotherapy, and cell engineering applications. This guide details experimental workflows, protocol enhancements, and troubleshooting strategies that bring the latest structural insights into practical laboratory use.

• Molidustat (BAY85-3934): HIF-PH Inhibitor in Renal Anemia Th

  2026-07-16

  Molidustat (BAY85-3934) is a selective hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that increases endogenous erythropoietin production and stabilizes HIF for the treatment of chronic kidney disease anemia. Its precise mechanism targets oxygen-sensing pathways, with evidence supporting efficacy in preclinical and clinical models, and demonstrates distinct pharmacological benefits over recombinant EPO therapies.

• Ionizing Radiation Alters Neuronal Differentiation via PI3K-

  2026-07-16

  This study uncovers how ionizing radiation (IR) drives altered neuronal differentiation in C17.2 mouse neural stem-like cells by activating the PI3K-STAT3-mGluR1 and PI3K-p53 signaling pathways. These findings provide mechanistic insight into potential contributors to IR-induced brain dysfunction and offer a valuable framework for future research on neural differentiation and epigenetic regulation.

• SP2509: Epigenetic Modulation and Apoptosis Induction in AML

  2026-07-15

  Explore how SP2509, a potent Lysine-specific demethylase 1 antagonist, advances cancer epigenetics research through precise modulation of histone methylation and apoptosis induction in acute myeloid leukemia models. This article provides a unique mechanistic and translational perspective distinct from existing resources.

• Belinostat (PXD101): Beyond Benchmarks to Functional Epigene

  2026-07-15

  Explore the nuanced utility of Belinostat (PXD101) in functional epigenetic profiling for cancer research. This article delivers advanced insights on in vitro response metrics, mechanistic depth, and practical assay implications, moving beyond conventional benchmarks.

• HDAC Inhibition in Neuroblastoma: Insights from M344 and Vor

  2026-07-14

  This article examines the evidence from Brumfield et al. (2025), which demonstrates that the HDAC inhibitor M344 effectively suppresses tumor growth and HDAC-related phenotypes in neuroblastoma models, outperforming vorinostat in several key assays. The findings underscore the therapeutic promise of HDAC inhibition in pediatric oncology and offer context for ongoing research in epigenetic modulation using agents such as vorinostat.

• Applied S-Adenosylmethionine for Methylation Reaction Workfl

  2026-07-14

  S-Adenosylmethionine (Ademetionine, SAM) enables high-fidelity methylation assays in both neuroepigenetic and metabolic research. This article delivers stepwise protocols, advanced applications, and troubleshooting strategies, empowering scientists to maximize assay reproducibility and translational impact using APExBIO's high-purity SAM.

• Establishing Patient-Derived Organoids for Breast Adenomyoep

  2026-07-13

  This study presents the first successful establishment and molecular characterization of organoids derived from adenomyoepithelioma (AME) of the breast. The resulting 3D culture system provides a clinically relevant platform for investigating AME pathogenesis and drug sensitivity, opening new avenues for rare breast tumor research.

• KG-501: Precision Modulation of CREB–KIX for Cancer Research

  2026-07-13

  KG-501 empowers researchers to dissect transcriptional coactivator networks in cancer and immune modulation assays with high specificity. Leveraging its unique inhibition of CREB–KIX and Myb–KIX interactions, KG-501 drives actionable insights in oncogenic signaling, macrophage polarization, and epigenetic regulation.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Workflow Guide

  2026-07-12

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of solubilizing hydrophobic, poorly water-soluble compounds—especially those with aromatic or phenyl groups—in pharmaceutical and biochemical research. It is validated for use as a drug formulation excipient or solubility enhancer; applications outside of these domains are not supported by current product or internal documentation.

• Cyanidin Chloride: Mechanistic Insights for Advanced Oxidati

  2026-07-10

  Explore Cyanidin Chloride as an anthocyanin polyphenolic antioxidant, focusing on its molecular mechanisms in oxidative stress research and cell protection. This article delivers a deeper mechanistic and methodological perspective for assay developers and translational scientists.

• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization via TL

  2026-07-09

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY) suppresses colitis-associated colorectal cancer (CAC) progression by promoting M1 macrophage polarization through the TLR4 pathway. This mechanistic insight advances our understanding of immune modulation in the tumor microenvironment and highlights avenues for integrating transcriptional coactivator disruption in cancer research.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Use and Protocols

  2026-07-09

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those containing aromatic or phenyl groups—by forming inclusion complexes that significantly improve their aqueous solubility. It should be used as a drug formulation excipient or pharmaceutical solubility enhancer; applications outside validated solubility and formulation workflows are not currently supported by product documentation.

• S-Adenosylhomocysteine: Beyond Methylation—Precision in Neur

  2026-07-08

  Explore the pivotal roles of S-Adenosylhomocysteine in neuro-metabolic research, with a unique focus on functional assay design, cellular methylation potential, and recent advances linking methylation dynamics to neural differentiation. Uncover advanced protocol insights and how SAH shapes next-generation experimental models.

11581 records 1/773 page Next 12345 下5页 Last page